SCHEDULE: Venrock Funds Disclose 9.9% Stake in Korro Bio

A group of Venrock entities and individuals have disclosed a 9.9% beneficial ownership stake in Korro Bio, Inc. through a Schedule 13G filing.

Summary

• A group of seven reporting persons, including Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC, Nimish Shah, and Bong Koh, collectively beneficially own 1,488,685 shares of Korro Bio, Inc. common stock.
• This ownership represents 9.9% of the class, rounded down from 9.99% due to EDGAR filing system limitations.
• The beneficial ownership includes 162,832 shares of common stock and pre-funded warrants for 265,462 shares held by VHCP III.
• VHCP Co-Investment III holds 16,253 shares of common stock and pre-funded warrants for 26,497 shares.
• VHCP EG holds 830,415 shares of common stock and pre-funded warrants for 1,353,806 shares.
• A "Beneficial Ownership Blocker" provision in the Pre-Funded Warrants prevents exercise if it would result in the group owning more than 9.99% of Korro Bio's outstanding common stock.
• The percentage is calculated based on 14,422,571 shares of common stock outstanding as of March 10, 2026, plus 479,185 shares issuable upon exercise of Pre-Funded Warrants.

Sentiment

Score: 6

Explanation: StockSavvy.ai views this as a moderately positive signal, as it indicates significant institutional interest and confidence from a reputable healthcare investor in Korro Bio, Inc., without suggesting any immediate negative implications.

Positives

• Significant institutional investment from Venrock, a reputable healthcare capital firm, indicates confidence in Korro Bio, Inc.
• The group's beneficial ownership is capped at 9.99% due to a blocker, suggesting a long-term passive investment strategy rather than an immediate control-seeking one.

Negatives

• No specific negatives are directly stated in this ownership disclosure filing.

Risks

• The "Beneficial Ownership Blocker" limits the immediate upside from warrant exercise if the group's ownership would exceed 9.99%, potentially restricting their ability to increase their stake rapidly.

Future Outlook

The filing does not contain specific forward-looking statements or guidance regarding Korro Bio, Inc.'s future performance or operations, focusing solely on beneficial ownership disclosure.

Industry Context

StockSavvy.ai notes that significant institutional investment from a healthcare-focused capital firm like Venrock in a biotechnology company such as Korro Bio, Inc. is a common indicator of investor confidence in the long-term potential of the company's pipeline or technology. This type of disclosure often signals that a well-regarded investor sees value in the company's sector position or strategic direction.

Comparison to Industry Standards

• StockSavvy.ai observes that a 9.9% stake is a substantial, but non-controlling, position for an institutional investor in a public company, aligning with typical passive investment strategies for venture capital or growth equity funds transitioning to public markets.
• For example, similar stakes are often seen in early-stage biotech companies where venture funds maintain significant holdings post-IPO, such as Flagship Pioneering's stakes in various biotech spin-offs or ARCH Venture Partners' positions in their portfolio companies.
• The beneficial ownership blocker is a standard mechanism to avoid triggering certain regulatory thresholds or control provisions.

Management Changes

Corporate Governance

Related Party Transactions

• The filing describes the beneficial ownership structure among various Venrock entities (Venrock Healthcare Capital Partners III, L.P., VHCP Co-Investment Holdings III, LLC, Venrock Healthcare Capital Partners EG, L.P., VHCP Management III, LLC, VHCP Management EG, LLC) and individuals (Nimish Shah, Bong Koh), which are related parties within the reporting group for the purpose of this Schedule 13G filing.

Stakeholder Impact

• Shareholders: Provides transparency regarding a significant institutional investor's stake, potentially signaling confidence in the company.
• Management: Awareness of a large, passive institutional holder.

Next Steps

• The filing does not explicitly mention future actions or milestones for Korro Bio, Inc. or the reporting persons beyond the ongoing requirement to comply with SEC filing regulations.

Key Dates

Recommendation

While the disclosure of a significant institutional stake from Venrock is a positive indicator of investor confidence in Korro Bio, Inc., a Schedule 13G filing primarily provides ownership information and does not offer sufficient detail on the company's operational performance, financial health, or strategic developments to warrant a 'buy' or 'sell' recommendation. A 'hold' recommendation is appropriate as this filing confirms existing institutional interest without introducing new fundamental data that would drastically alter the investment thesis.

Keywords

Korro Bio, Venrock, Schedule 13G, Beneficial Ownership, Common Stock, Pre-Funded Warrants, Institutional Investment, SEC Filing, Healthcare Capital